A Phase 3 interventional study of Rifaximin and Placebo in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 3rd largest by enrollment, is one of 2 that started in 2005, is one of 4 in phase 3, and was the 2nd registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Belgium, Netherlands
Ages 18–80
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2005.
This study's enrollment of 299 is above the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 94 across the 18 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 7 studies filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
Drug: Rifaximin
Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
Drug: Placebo
Oral
Also known as: Xifaxan®
Oral
Time To The First Breakthrough Overt HE Episode
Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented.
Time frame: Baseline up to 6 Months (168 days)
Time To First HE-related Hospitalization
Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization. Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of participants with their first HE-related hospitalization per interval is presented. The number of events of the first HE-related hospitalization during the treatment interval is presented.
Time frame: Baseline up to 6 months
Time To Any Increase From Baseline In Conn Score
Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.
Time frame: Baseline up to 6 months
Time To Any Increase From Baseline In Asterixis Grade
Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.
Time frame: Baseline up to 6 months
Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment
The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).
Time frame: Baseline, 6 months (End Of Treatment)
Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment
Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.
Time frame: Baseline, Month 6 (End Of Treatment)
| Milestone | Rifaximin | Placebo |
|---|---|---|
| Started | 140 | 159 |
| Received at least 1 dose of study drug | 140 | 159 |
| Completed | 88 | 66 |
| Not completed | 52 | 93 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Liver transplant | 0 | 1 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Death | 6 | 3 |
| Withdrew: Withdrawal by subject | 6 | 9 |
| Withdrew: Adverse event | 8 | 7 |
| Withdrew: Breakthrough overt he episode | 28 | 69 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Cocaine abuse | 1 | 0 |
| Withdrew: Severe gastrointestinal bleed | 1 | 0 |
Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented.
| events | Rifaximin | Placebo |
|---|---|---|
| 0 to <28 Days | 13 | 20 |
| 28 to <56 Days | 4 | 23 |
| 56 to <84 Days | 6 | 14 |
| 84 to <140 Days | 7 | 10 |
| 140 to <168 Days | 1 | 6 |
| ≥168 Days | 0 | 0 |
Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization. Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of participants with their first HE-related hospitalization per interval is presented. The number of events of the first HE-related hospitalization during the treatment interval is presented.
| events | Rifaximin | Placebo |
|---|---|---|
| 0 to <28 Days | 4 | 11 |
| 28 to <56 Days | 4 | 12 |
| 56 to <84 Days | 4 | 7 |
| 84 to 140 Days | 5 | 4 |
| 140 to <168 Days | 2 | 2 |
| ≥168 Days | 0 | 0 |
Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.
| events | Rifaximin | Placebo |
|---|---|---|
| 0 to <28 Days | 17 | 26 |
| 28 to <56 Days | 5 | 21 |
| 56 to <84 Days | 9 | 15 |
| 84 to <140 Days | 5 | 10 |
| 140 to <168 Days | 0 | 5 |
| ≥168 Days | 1 | 0 |
Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.
| events | Rifaximin | Placebo |
|---|---|---|
| 0 to <28 Days | 13 | 20 |
| 28 to <56 Days | 7 | 15 |
| 56 to <84 Days | 7 | 4 |
| 84 to <140 Days | 3 | 6 |
| 140 to <168 Days | 1 | 4 |
| ≥168 Days | 1 | 1 |
The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).
| score on a scale | Rifaximin | Placebo |
|---|---|---|
| Baseline | 3.28 ± 1.326 | 3.34 ± 1.406 |
| Change from Baseline | 0.30 ± 1.262 | 0.11 ± 1.319 |
Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.
| microgram per deciliter (ug/dL) | Rifaximin | Placebo |
|---|---|---|
| Baseline | 87.9 ± 47.76 | 92.1 ± 55.24 |
| Change from Baseline | -5.7 ± 46.77 | -1.2 ± 60.98 |
Collected over Baseline up to 6.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin | — | 51/140 (36.4%) | 91/140 (65%) |
| Placebo | — | 63/159 (39.6%) | 101/159 (63.5%) |
| Event | Rifaximin | Placebo |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 16/140 | 34/159 |
| Hepatic cirrhosisHepatobiliary disorders | 3/140 | 6/159 |
| AscitesGastrointestinal disorders | 4/140 | 4/159 |
| AnaemiaBlood and lymphatic system disorders | 4/140 | 0/159 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 4/140 | 2/159 |
| PneumoniaInfections and infestations | 4/140 | 1/159 |
| Renal failure acuteRenal and urinary disorders | 2/140 | 4/159 |
| VomitingGastrointestinal disorders | 3/140 | 0/159 |
| Generalised oedemaGeneral disorders | 3/140 | 2/159 |
| CellulitisInfections and infestations | 3/140 | 2/159 |
| Event | Rifaximin | Placebo |
|---|---|---|
| Oedema peripheralGeneral disorders | 21/140 | 13/159 |
| NauseaGastrointestinal disorders | 19/140 | 21/159 |
| DiarrhoeaGastrointestinal disorders | 15/140 | 21/159 |
| DizzinessNervous system disorders | 18/140 | 12/159 |
| FatigueGeneral disorders | 17/140 | 18/159 |
| AscitesGastrointestinal disorders | 15/140 | 13/159 |
| HeadacheNervous system disorders | 14/140 | 17/159 |
| Hepatic encephalopathyNervous system disorders | 8/140 | 16/159 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 13/140 | 11/159 |
| PruritusSkin and subcutaneous tissue disorders | 13/140 | 10/159 |
Randomized participants who received at least 1 dose of study drug (ITT population).
| Age, Continuous(years) | Rifaximin | Placebo | Total |
|---|---|---|---|
| Mean | 55.5 ± 9.57 | 56.8 ± 9.18 | 56.2 ± 56.0 |
| Sex: Female, Male(Participants) | Rifaximin | Placebo | Total |
|---|---|---|---|
| Female | 65 | 52 | 117 |
| Male | 75 | 107 | 182 |
No study locations are listed for this record.
Ran from Dec 2005 to primary completion in Aug 2008, 31 months.
Results were first posted in Aug 2019, 10 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →